AP2000001898A0 - Vitronectin receptor antagonists - Google Patents
Vitronectin receptor antagonistsInfo
- Publication number
- AP2000001898A0 AP2000001898A0 APAP/P/2000/001898A AP2000001898A AP2000001898A0 AP 2000001898 A0 AP2000001898 A0 AP 2000001898A0 AP 2000001898 A AP2000001898 A AP 2000001898A AP 2000001898 A0 AP2000001898 A0 AP 2000001898A0
- Authority
- AP
- ARIPO
- Prior art keywords
- vitronectin receptor
- receptor antagonists
- inflamamation
- restenosis
- osteoporosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7761098P | 1998-03-10 | 1998-03-10 | |
| US9606398P | 1998-08-11 | 1998-08-11 | |
| PCT/US1999/005232 WO1999045927A1 (fr) | 1998-03-10 | 1999-03-10 | Antagonistes du recepteur de la vitronectine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2000001898A0 true AP2000001898A0 (en) | 2000-09-30 |
Family
ID=26759473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/2000/001898A AP2000001898A0 (en) | 1998-03-10 | 1999-03-10 | Vitronectin receptor antagonists |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1061921A4 (fr) |
| JP (1) | JP2002506033A (fr) |
| KR (1) | KR20010041812A (fr) |
| CN (1) | CN1299282A (fr) |
| AP (1) | AP2000001898A0 (fr) |
| AR (1) | AR015241A1 (fr) |
| AU (1) | AU758498B2 (fr) |
| BG (1) | BG104824A (fr) |
| BR (1) | BR9908636A (fr) |
| CA (1) | CA2323208A1 (fr) |
| CO (1) | CO5080762A1 (fr) |
| DZ (1) | DZ2741A1 (fr) |
| EA (1) | EA200000921A1 (fr) |
| HU (1) | HUP0101143A3 (fr) |
| ID (1) | ID26223A (fr) |
| IL (1) | IL138245A0 (fr) |
| NO (1) | NO20004503L (fr) |
| OA (1) | OA12189A (fr) |
| PE (1) | PE20000323A1 (fr) |
| PL (1) | PL342881A1 (fr) |
| SK (1) | SK13292000A3 (fr) |
| TR (1) | TR200002625T2 (fr) |
| UY (2) | UY25421A1 (fr) |
| WO (1) | WO1999045927A1 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19939980A1 (de) * | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Inhibitoren des Integrins alphavbeta¶3¶ |
| DE19939981A1 (de) * | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Neue Inhibitoren des Integrins alphavß3 |
| US6881736B1 (en) | 1999-09-07 | 2005-04-19 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
| EG24179A (en) * | 1999-09-07 | 2008-09-28 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
| US6448278B2 (en) | 1999-12-23 | 2002-09-10 | Pfizer Inc. | Procollagen C-proteinase inhibitors |
| GB9930570D0 (en) * | 1999-12-23 | 2000-02-16 | Pfizer Ltd | Therapy |
| FR2808798A1 (fr) * | 2000-05-09 | 2001-11-16 | Hoechst Marion Roussel Inc | Nouveaux derives antagonistes du recepteur de la vitronectine |
| US6900232B2 (en) | 2000-06-15 | 2005-05-31 | Pharmacia Corporation | Cycloalkyl alkanoic acids as integrin receptor antagonists |
| US6531494B1 (en) | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
| US6645993B2 (en) | 2001-03-30 | 2003-11-11 | Warner-Lambert Company | 3-heterocyclylpropanohydroxamic acid PCP inhibitors |
| US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
| WO2005049589A2 (fr) * | 2003-10-14 | 2005-06-02 | Cadila Healthcare Limited | Nouveaux composes heterocycliques |
| EP1721905A4 (fr) * | 2004-03-05 | 2009-11-18 | Taisho Pharmaceutical Co Ltd | Derive de thiazole |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| US7262210B2 (en) | 2005-04-20 | 2007-08-28 | Janssen Pharmaceutica N.V. | Fluorinated pyridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls |
| PL3040329T3 (pl) | 2013-08-29 | 2019-04-30 | Kyoto Pharma Ind | Związek aromatyczny i jego zastosowanie w leczeniu chorób związanych z metabolizmem kości |
| SI3929196T1 (sl) | 2013-09-24 | 2023-11-30 | Fujifilm Corporation | Farmacevtska sestava spojine, ki vsebuje dušik ali njegovo sol ali njegov kovinski kompleks |
| BR112016027778A2 (pt) | 2014-05-30 | 2017-08-15 | Pfizer | Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica |
| WO2023275715A1 (fr) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Métabolites de modulateurs sélectifs du récepteur des androgènes |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR199801254T2 (xx) * | 1995-12-29 | 1998-10-21 | Smithkline Beecham Corporation | Vitronektin resept�r� antagonistleri. |
| JP2000502708A (ja) * | 1995-12-29 | 2000-03-07 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体拮抗物質 |
-
1999
- 1999-03-10 UY UY25421A patent/UY25421A1/es unknown
- 1999-03-10 AP APAP/P/2000/001898A patent/AP2000001898A0/en unknown
- 1999-03-10 IL IL13824599A patent/IL138245A0/xx unknown
- 1999-03-10 CN CN99805833A patent/CN1299282A/zh active Pending
- 1999-03-10 KR KR1020007010091A patent/KR20010041812A/ko not_active Application Discontinuation
- 1999-03-10 TR TR2000/02625T patent/TR200002625T2/xx unknown
- 1999-03-10 HU HU0101143A patent/HUP0101143A3/hu unknown
- 1999-03-10 EP EP99909952A patent/EP1061921A4/fr not_active Withdrawn
- 1999-03-10 WO PCT/US1999/005232 patent/WO1999045927A1/fr not_active Application Discontinuation
- 1999-03-10 AU AU29033/99A patent/AU758498B2/en not_active Ceased
- 1999-03-10 DZ DZ990042A patent/DZ2741A1/fr active
- 1999-03-10 EA EA200000921A patent/EA200000921A1/ru unknown
- 1999-03-10 PL PL99342881A patent/PL342881A1/xx unknown
- 1999-03-10 AR ARP990101019A patent/AR015241A1/es not_active Application Discontinuation
- 1999-03-10 CO CO99014712A patent/CO5080762A1/es unknown
- 1999-03-10 BR BR9908636-0A patent/BR9908636A/pt not_active Application Discontinuation
- 1999-03-10 SK SK1329-2000A patent/SK13292000A3/sk unknown
- 1999-03-10 ID IDW20001737A patent/ID26223A/id unknown
- 1999-03-10 OA OA00000248A patent/OA12189A/en unknown
- 1999-03-10 JP JP2000535342A patent/JP2002506033A/ja not_active Withdrawn
- 1999-03-10 PE PE1999000188A patent/PE20000323A1/es not_active Application Discontinuation
- 1999-03-10 CA CA002323208A patent/CA2323208A1/fr not_active Abandoned
- 1999-05-19 UY UY25519A patent/UY25519A1/es unknown
-
2000
- 2000-09-08 NO NO20004503A patent/NO20004503L/no unknown
- 2000-10-03 BG BG104824A patent/BG104824A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DZ2741A1 (fr) | 2003-09-08 |
| JP2002506033A (ja) | 2002-02-26 |
| BR9908636A (pt) | 2002-01-08 |
| UY25421A1 (es) | 2001-07-31 |
| CA2323208A1 (fr) | 1999-09-16 |
| HUP0101143A2 (hu) | 2001-08-28 |
| NO20004503L (no) | 2000-10-10 |
| IL138245A0 (en) | 2001-10-31 |
| NO20004503D0 (no) | 2000-09-08 |
| AR015241A1 (es) | 2001-04-18 |
| KR20010041812A (ko) | 2001-05-25 |
| TR200002625T2 (tr) | 2000-12-21 |
| UY25519A1 (es) | 1999-12-13 |
| CO5080762A1 (es) | 2001-09-25 |
| AU758498B2 (en) | 2003-03-20 |
| SK13292000A3 (sk) | 2001-06-11 |
| AU2903399A (en) | 1999-09-27 |
| OA12189A (en) | 2006-05-09 |
| EP1061921A4 (fr) | 2005-03-30 |
| PE20000323A1 (es) | 2000-05-24 |
| CN1299282A (zh) | 2001-06-13 |
| BG104824A (en) | 2001-05-31 |
| ID26223A (id) | 2000-12-07 |
| EA200000921A1 (ru) | 2001-04-23 |
| PL342881A1 (en) | 2001-07-16 |
| WO1999045927A1 (fr) | 1999-09-16 |
| EP1061921A1 (fr) | 2000-12-27 |
| HUP0101143A3 (en) | 2002-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2000001898A0 (en) | Vitronectin receptor antagonists | |
| MX9805253A (es) | Antagonistas del receptor de vitronectina. | |
| AP1463A (en) | Vitronectin receptor antagonists. | |
| EP0961613A4 (fr) | Methodes et compositions pour le traitement des troubles de la resorption osseuse, y compris l'osteoporose | |
| NZ329431A (en) | Purine derivatives and medicaments thereof | |
| NZ336560A (en) | 10,11-dihydro-3-[substituted pyridyl-1-alkoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid derivatives useful as vitronectin receptor antagonists | |
| MY124786A (en) | Bis-arylsulfones | |
| NO20001514L (no) | Vitronectin-reseptor-antagonist | |
| IL150060A0 (en) | Novel purines | |
| PL337361A1 (en) | Chalkones of antiproliferative activity | |
| DE60015508D1 (de) | C-16 ungesätigte fp-selektive prostaglandin analoge | |
| AP1534A (en) | Vitronectin receptor antagonists. | |
| BG105962A (en) | Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders | |
| MXPA02001204A (es) | Compuestos calciliticos. | |
| PL371310A1 (en) | Use of substituted 3-phenyl-5-alkoxy-1,3,4-oxdiazole-2-one for producing medicaments that inhibit pancreatic lipase | |
| DE69911017D1 (en) | Arylsulfonanilid-phosphate | |
| HK1031337A1 (en) | Process for the synthesis of finely divided antiperspirant active ingredient suspensions. | |
| TWI255813B (en) | Compounds for use as alphavbeta3 receptor antagonists | |
| WO2000007544A3 (fr) | Antagonistes du recepteur de la proteine s | |
| GB9920910D0 (en) | Novel chalcones | |
| AU3386199A (en) | N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents) | |
| NZ506750A (en) | Vitronectin receptor antagonists useful in the treatment of inflammation, cancer and cardiovascular disorders | |
| MXPA02002486A (es) | Uso de dexrazoxano para tratar la psoriasis. | |
| IT1311582B1 (it) | Ortesi ortopedica per il trattamento di epicondiliti. | |
| MY132635A (en) | Cycloalkyl derivatives as inhibitors of bone resporption and vitronectin receptor antagonists |